Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 24.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,760 shares of the biopharmaceutical company's stock after purchasing an additional 4,532 shares during the period. GAMMA Investing LLC's holdings in Gilead Sciences were worth $2,550,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GILD. Annis Gardner Whiting Capital Advisors LLC boosted its stake in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 216 shares in the last quarter. Whipplewood Advisors LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at $35,000. Synergy Investment Management LLC purchased a new position in Gilead Sciences in the 4th quarter worth $40,000. Lee Danner & Bass Inc. bought a new stake in Gilead Sciences in the fourth quarter worth $41,000. Finally, Fourth Dimension Wealth LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at about $54,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Morgan Stanley increased their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Bank of America upped their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Finally, Oppenheimer dropped their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Stock Up 0.2%

Gilead Sciences stock traded up $0.27 during trading hours on Wednesday, reaching $112.00. The stock had a trading volume of 3,272,547 shares, compared to its average volume of 7,670,437. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The company has a market cap of $139.32 billion, a price-to-earnings ratio of 23.58, a PEG ratio of 0.72 and a beta of 0.29. The business's 50 day moving average price is $106.65 and its 200-day moving average price is $103.61. Gilead Sciences, Inc. has a 52 week low of $66.01 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm's revenue was down .3% compared to the same quarter last year. During the same period last year, the business posted ($1.32) earnings per share. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.82%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $275,425.00. Following the sale, the chief financial officer directly owned 165,110 shares of the company's stock, valued at approximately $18,190,168.70. This trade represents a 1.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the sale, the insider owned 120,168 shares of the company's stock, valued at $13,238,908.56. This trade represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 58,500 shares of company stock worth $6,340,745. 0.27% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.